Vetter's clinical manufacturing services continue to attract new business.
Vetter recently announced a series of structural changes in its Development Service Division in a move to support its customer base.
Dr. Susanne Resatz, who was formerly manager of process development and manufacturing at the company’s clinical development facility in Chicago, Illinois, has assumed the role of president. Resatz will be fully responsible for the site’s operations. Dr. Claudia Roth, who formerly held this position, will repatriate to the company headquarters in Ravensburg, Germany where she will head up the newly created “Innovation” department. Both Resatz and Roth have been with Vetter’s US facility since its opening in 2009, and were instrumental in its early construction through to its becoming fully operational in October 2011.
Resatz’s expertise includes designing and implementing highly efficient, high-quality manufacturing processes for early-stage products. Through her work with biopharmaceutical companies around the globe, she has had experience meeting the requirements of a broad variety of international regulatory authorities. She holds a PhD in biomedical engineering from the Vienna University of Technology.
Roth will be heading up the newly created “Innovation” department in Ravensburg, which will be focused on anticipating and preparing for future customer and product development needs including filling processes and technology, as well as packaging solutions.
Vetter’s Chicago facility, which an expansion of Vetter Development Service, employs more than 150 personnel in Europe and the United States. Implementing its first manufacturing facility in the US for offering early development support has been strategic to Vetter’s plan for worldwide growth.
Vetter also announced that Dr. Paul Nelles, who headed Vetter´s global Development Service activities, will take early retirement after 11 years of service with Vetter. His replacement, Dr. Claus Feussner, formerly vice president Quality Control, has assumed the title of senior vice President of Vetter Development Service effective September 1. Nelles will continue with his efforts at Vetter until mid-2015 to help with the transition.
Source: Vetter
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.